MESO Stocktwits, News and Mentions. Forecasting Mesoblast Limited Sentiments







6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

February 15, 2024 Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…

MESO Stock News and Mentions of Mesoblast Limited Stocktwits

Updated: March 28, 2024 (13:18)

Sector: Healthcare

Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.

We meticulously analyze the sentiment trend in each article for the last 60 days where Mesoblast Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Mesoblast Limited (MESO).

You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Mesoblast stocks.


Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles

News and Mentions of Mesoblast Limited (MESO)

March 28, 2024 (12:30) / "Benzinga" (by Avi Kapoor)

Top 5 Health Care Stocks That May Plunge In March - Mesoblast ( NASDAQ:MESO ) , Inozyme Pharma ( NASDAQ:INZY )

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (15:00) / "Zacks Commentary" (by Zacks Equity Research)

Mesoblast ( MESO ) to File Pediatric GVHD Drug BLA, Stock Up

Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
In Article Trend: Neutral
March 27, 2024 (12:14) / "Benzinga" (by Avi Kapoor)

Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket - MariaDB ( NYSE:MRDB )

Shares of MariaDB plc MRDB rose sharply in today's pre-market trading after Progress Software PRGS announced that it is possibly considering an offer for the company. MariaDB shares jumped 100.4% to $0.4530 in pre-market trading Here are some other stocks moving in pre-market trading.
In Article Trend: Somewhat-Bullish
March 27, 2024 (09:39) / "Benzinga" (by Avi Kapoor)

GameStop Posts Downbeat Results, Joins Direct Digital, Forge Global And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - GameStop ( NYSE:GME ) , Direct Digital Holdings ( NASDAQ:DRCT )

U.S. stock futures were higher this morning, with the Dow futures gaining by more than 100 points on Wednesday. Shares of GameStop Corp. GME fell sharply in today's pre-market trading as the company posted weaker-than-expected results for its fourth quarter on Tuesday.
In Article Trend: Neutral
March 26, 2024 (19:08) / "Benzinga" (by Avi Kapoor)

Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates - Cardlytics ( NASDAQ:CDLX ) , AppTech Payments ( NASDAQ:APCX )

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday. The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500 also rose, gaining, 0.17% to 5,227.03. Consumer discretionary shares jumped by 0.6% on Monday.
In Article Trend: Somewhat-Bullish
March 26, 2024 (16:47) / "Benzinga" (by Vandana Singh)

Why Is Mesoblast Stock Trading Higher On Tuesday? - Mesoblast ( NASDAQ:MESO )

Monday, the FDA informed Mesoblast Limited MESO that following additional consideration, the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application ( BLA ) for remestemcel-L for pediatric patients with ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (16:08) / "Benzinga" (by Avi Kapoor)

Dow Gains 100 Points; McCormick Posts Upbeat Results - Cardlytics ( NASDAQ:CDLX ) , AppTech Payments ( NASDAQ:APCX )

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on Tuesday. The Dow traded up 0.25% to 39,413.30 while the NASDAQ rose 0.27% to 16,448.55. The S&P 500 also rose, gaining, 0.27% to 5,232.36. Consumer discretionary shares jumped by 0.8% on Monday.
In Article Trend: Somewhat-Bullish
March 26, 2024 (12:00) / "Benzinga" (by Avi Kapoor)

Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket - Stoke Therapeutics ( NASDAQ:STOK )

Shares of Stoke Therapeutics, Inc. STOK rose sharply in today's pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Stoke Therapeutics shares jumped 69.7% to $11.03 in pre-market trading Here are some other stocks moving in ...
In Article Trend: Neutral
March 26, 2024 (02:34) / "GlobeNewswire" (by Mesoblast Limited)

United States Food & Drug Administration ( FDA ) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease ( SR-aGVHD )

NEW YORK, March 25, 2024 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its ...
In Article Trend: Neutral
March 13, 2024 (23:30) / "GlobeNewswire" (by Mesoblast Limited)

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

NEW YORK, March 13, 2024 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was ...
In Article Trend: Neutral
March 11, 2024 (13:24) / "Benzinga" (by Vandana Singh)

Why Is Mesoblast Stock Trading Higher On Monday? - Mesoblast ( NASDAQ:MESO )

Monday, Mesoblast Limited MESO announced that the FDA supports an accelerated approval pathway for rexlemestrocel-L, its allogeneic mesenchymal precursor cell product, for end-stage ischemic heart failure with reduced ejection fraction ( HFrEF ) and a left ventricular assist device ( LVAD ) .
In Article Trend: Neutral
March 11, 2024 (12:08) / "Benzinga" (by Avi Kapoor)

Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket - Avenue Therapeutics ( NASDAQ:ATXI ) , Auddia ( NASDAQ:AUUD )

Shares of Fangdd Network Group Ltd. DUO rose sharply in today's pre-market trading after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector. Fangdd Network Group shares jumped 78.3% to $1.08 in pre-market trading
In Article Trend: Neutral
March 10, 2024 (23:54) / "GlobeNewswire" (by Mesoblast Limited)

United States Food & Drug Administration ( FDA ) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device ( LVAD )

NEW YORK, March 10, 2024 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA supports an accelerated approval pathway for rexlemestrocel-L, Mesoblast's allogeneic mesenchymal ...
In Article Trend: Neutral
March 6, 2024 (06:50) / "Stocknews.com" (by Defense World Staff)

Mesoblast ( NASDAQ:MESO ) Rating Increased to Hold at StockNews.com

Mesoblast ( NASDAQ:MESO - Get Free Report ) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a report released on Monday. Separately, Cantor Fitzgerald restated an "overweight" rating on shares of Mesoblast in a research note on Friday, January 12th.
In Article Trend: Somewhat-Bullish
February 28, 2024 (22:57) / "GlobeNewswire" (by Mesoblast Limited)

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

NEW YORK, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023.
In Article Trend: Neutral
February 26, 2024 (12:00) / "GlobeNewswire" (by Mesoblast Limited)

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Feb. 26, 2024 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the six months ended December 31, 2023.
In Article Trend: Neutral
February 15, 2024 (00:46) / "GlobeNewswire" (by Mesoblast Limited)

United States Food & Drug Administration ( FDA ) Grants Mesoblast Orphan-Drug Designation for Revascor® ( Rexlemestrocel-L ) in Children With Congenital Heart Disease

NEW YORK, Feb. 14, 2024 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration ( FDA ) has granted its allogeneic cell therapy Revascor® ( ...
In Article Trend: Somewhat-Bullish
February 13, 2024 (13:18) / "Benzinga" (by Faith Ashmore)

BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society ( ORS ) 2024 Annual Meeting - BioRestorative Therapies ( NASDAQ:BRTX )

BioRestorative Therapies BRTX is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions such as obesity and diabetes.
In Article Trend: Neutral
February 13, 2024 (06:46) / "Stocknews.com" (by Defense World Staff)

Mesoblast ( NASDAQ:MESO ) Rating Increased to Sell at StockNews.com

Mesoblast ( NASDAQ:MESO - Get Free Report ) was upgraded by equities researchers at StockNews.com to a "sell" rating in a report released on Tuesday. Separately, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Mesoblast in a research note on Friday, January 12th.
In Article Trend: Somewhat-Bullish
January 31, 2024 (02:13) / "GlobeNewswire" (by Mesoblast Limited)

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

NEW YORK, Jan. 30, 2024 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO; ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2023.
In Article Trend: Neutral



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.